P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE

Detalles Bibliográficos
Autores principales: T., COATES, A., LAL, R., BROWN, T., KALFA, J., KWIATKOWSKI, J., BREVARD, C., TRENOR, K., WOOD, S., SHETH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Poster Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429762/
http://dx.doi.org/10.1097/01.HS9.0000873112.02265.19
_version_ 1784779559101530112
author T., COATES
A., LAL
R., BROWN
T., KALFA
J., KWIATKOWSKI
J., BREVARD
C., TRENOR
K., WOOD
S., SHETH
author_facet T., COATES
A., LAL
R., BROWN
T., KALFA
J., KWIATKOWSKI
J., BREVARD
C., TRENOR
K., WOOD
S., SHETH
author_sort T., COATES
collection PubMed
description
format Online
Article
Text
id pubmed-9429762
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94297622022-09-01 P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE T., COATES A., LAL R., BROWN T., KALFA J., KWIATKOWSKI J., BREVARD C., TRENOR K., WOOD S., SHETH Hemasphere Poster Presentations Lippincott Williams & Wilkins 2022-08-16 /pmc/articles/PMC9429762/ http://dx.doi.org/10.1097/01.HS9.0000873112.02265.19 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Poster Presentations
T., COATES
A., LAL
R., BROWN
T., KALFA
J., KWIATKOWSKI
J., BREVARD
C., TRENOR
K., WOOD
S., SHETH
P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
title P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
title_full P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
title_fullStr P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
title_full_unstemmed P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
title_short P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
title_sort p-055: trial in progress: a phase 2, open-label study evaluating the safety and efficacy of the erythrocyte pyruvate kinase activator etavopivat in patients with thalassemia or sickle cell disease
topic Poster Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429762/
http://dx.doi.org/10.1097/01.HS9.0000873112.02265.19
work_keys_str_mv AT tcoates p055trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease
AT alal p055trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease
AT rbrown p055trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease
AT tkalfa p055trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease
AT jkwiatkowski p055trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease
AT jbrevard p055trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease
AT ctrenor p055trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease
AT kwood p055trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease
AT ssheth p055trialinprogressaphase2openlabelstudyevaluatingthesafetyandefficacyoftheerythrocytepyruvatekinaseactivatoretavopivatinpatientswiththalassemiaorsicklecelldisease

Ejemplares similares